Recruit new patients and continue follow-up of the BLCS cohort to update data on smoking, diet, physical activity, medication use, weight, other exposures, overall mortality, and other outcomes
Continue to collect and update oncogenic (somatic driver) mutations for the BLCS cohort using existing clinical screening programs supported by existing DF/HCC mechanisms
Maintain data management and quality control systems to maximize the value of the BLCS data for scientific analyses conducted by internal and external investigators
Continue the identification, tracking, and ongoing utilization of FFPE tissue blocks for characterization.
Expand a prospective dimension of the existing cohort. Prospective data and biosamples will be collected at regular follow-up of lung cancer patients, which will be valuable for studies in relation to treatment efficacy, toxicity, and survival, as well as ongoing characterization of relevant biomarkers.
